Advanced in Primary Hyperoxaluria

Brigitte Llanas

Bordeaux, FR 
Advanced in Primary Hyperoxaluria
Bordeaux, FR 
OverviewLocationsClinical Research

Overview

Brigitte Llanas practices in Bordeaux, France. Ms. Llanas is rated as an Advanced expert by MediFind in the treatment of Primary Hyperoxaluria. Her top areas of expertise are D-Plus Hemolytic Uremic Syndrome, D-Minus Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, Thrombocytopenia, and Kidney Transplant.

Her clinical research consists of co-authoring 36 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of Primary Hyperoxaluria.

Gender
Female

Locations

Bordeaux, France
Other Locations
Toulouse, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Multicentre Validation of a Fetal Urine Peptidome-based Classifier to Predict Post-natal Renal Function in Posterior Urethral Valves
Multicentre Validation of a Fetal Urine Peptidome-based Classifier to Predict Post-natal Renal Function in Posterior Urethral Valves
Enrollment Status: Unknown
Publish Date: August 23, 2023
Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Enrollment Status: Completed
Publish Date: December 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo
Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo
Enrollment Status: Completed
Publish Date: July 12, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

36 Total Publications

Long-term tolvaptan therapy in a case of very early-onset polycystic kidney disease.
Long-term tolvaptan therapy in a case of very early-onset polycystic kidney disease.
Journal: Pediatric nephrology (Berlin, Germany)
Published: November 07, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Llanas's expertise for a condition
ConditionClose
      View All 17 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile